| 000 | 01823 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516125819.0 | ||
| 264 | 0 | _c20130322 | |
| 008 | 201303s 0 0 eng d | ||
| 022 | _a1527-9995 | ||
| 024 | 7 |
_a10.1016/j.urology.2012.09.019 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan den Eertwegh, Alfonsus J M | |
| 245 | 0 | 0 |
_aSafety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. _h[electronic resource] |
| 260 |
_bUrology _cJan 2013 |
||
| 300 |
_a143-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnemia _xchemically induced |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aDyspnea _xchemically induced |
| 650 | 0 | 4 | _aEverolimus |
| 650 | 0 | 4 |
_aFatigue _xchemically induced |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperglycemia _xchemically induced |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPneumonia _xchemically induced |
| 650 | 0 | 4 |
_aSirolimus _xadverse effects |
| 650 | 0 | 4 |
_aStomatitis _xchemically induced |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKarakiewicz, Pierre | |
| 700 | 1 | _aBavbek, Sevil | |
| 700 | 1 | _aRha, Sun Young | |
| 700 | 1 | _aBracarda, Sergio | |
| 700 | 1 | _aBahl, Amit | |
| 700 | 1 | _aOu, Yen-chuan | |
| 700 | 1 | _aKim, Dennis | |
| 700 | 1 | _aPanneerselvam, Ashok | |
| 700 | 1 | _aAnak, Oezlem | |
| 700 | 1 | _aGrünwald, Viktor | |
| 773 | 0 |
_tUrology _gvol. 81 _gno. 1 _gp. 143-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.urology.2012.09.019 _zAvailable from publisher's website |
| 999 |
_c22377593 _d22377593 |
||